Cáncer y vacunas. Presente y futuro

  1. Mª Teófila Vicente-Herrero 157
  2. José Lorenzo Bravo-Grande 256
  3. Mª Victoria Ramírez-Iñiguez de la Torre 3457
  1. 1 Grupo ADEMA-SALUD del Instituto Universitario de Ciencias de la Salud-IUNICS Illes Balears (España)
  2. 2 Asociación Española de Vacunología
    info

    Asociación Española de Vacunología

    Madrid, España

  3. 3 Medicina del Trabajo en SPP Grupo Correos Albacete y Cuenca.
  4. 4 Medicina del Trabajo del SPA ITEM-prevención
  5. 5 Asociación Española de Especialistas en Medicina del Trabajo (AEEMT).
  6. 6 Grupo Cáncer y Trabajo y Grupo de Vacunas.
  7. 7 Grupo Cáncer y Trabajo y de Guías y Protocolos.
Show affiliations +
Journal:
Academic Journal of Health Sciences: Medicina Balear

ISSN: 2255-0560

Year of publication: 2023

Volume: 38

Issue: 4

Pages: 69-75

Type: Article

DOI: 10.3306/AJHS.2023.38.04.69 DIALNET GOOGLE SCHOLAR lock_openIbdigital editor

Abstract

Introduction. In the last century, vaccines have been the most effective public health tool to reduce mortality and morbidity from infectious diseases. In cancer prevention and treatment, the current trend is towards personalized treatment, including vaccines along with other novel treatments such as immunotherapy. Methodology. A literature review was carried out in December 2022 in the PubMed/Medline databases of scientific articles published online to date, without limiting the search period, using the following keywords and MeSH terms: cancer and vaccines; Cancer and therapeutic vaccines; colorectal cancer, Skin cancer, Breast cancer, Prostate cancer, Kidney cancer, Lung cancer; Cancer and preventive vaccines HPV, Hepatitis B. Results. The results obtained in the search with the generic concept (cancer and vaccines) and, specifically, those related to the therapeutic use of vaccines in cancer almost double those referring to preventive use. The references to lung, skin and breast cancer and, in preventive use, those for papillomavirus and hepatitis B stand out. Conclusion. The development of vaccines for cancer treatment is challenging, as vaccine intervention must combat an immune system that has been constrained by mechanisms that sustain the immune response and held back by those that maintain the disease in an attempt at self-tolerance. The expected future results of such vaccines are promising.

Bibliographic References

  • Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med. 2014 Jun;6(6):708-20.
  • Zhou J, Kroll AV, Holay M, Fang RH, Zhang L. Biomimetic Nanotechnology toward Personalized Vaccines. Adv Mater. 2020 Apr;32(13):e1901255.
  • Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: Building a bridge over troubled waters. Cell. 2022 Jul 21;185(15):2770-88.
  • Martínez-Gómez X, Curran A, Campins M, Alemany L, Rodrigo- Pendás JÁ, Borruel N, Castellsagué X, Díaz-de-Heredia C, Moraga-Llop FA, Del Pino M, Torné A. Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. Euro Surveill. 2019 Feb;24(7):1700857.
  • Méndez-Martínez R, Rivera-Martínez NE, Crabtree-Ramírez B, Sierra- Madero JG, Caro-Vega Y, Galván SC, de León DC, García-Carrancá A. Multiple human papillomavirus infections are highly prevalent in the anal canal of human immunodeficiency virus-positive men who have sex with men. BMC Infect Dis. 2014 Dec 16;14:671.
  • Cortés J, Gil A, Martinón F, Bosch FX, Ramón y Cajal JM. Vaccination against human papilloma virus in men: situation and proposals“. Acad J Health Sci 2022; 37 (3): 166-70.
  • Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B Vaccines. J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S343-S351
  • Shechter O, Sausen DG, Gallo ES, Dahari H, Borenstein R. Epstein-Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments. Int J Mol Sci. 2022 Nov 19;23(22):14389.
  • Giarelli E. Cancer vaccines: a new frontier in prevention and treatment. Oncology (Williston Park). 2007 Oct;21(11 Suppl Nurse Ed):11-7; discussion 18.
  • Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification. Clin Cancer Res. 2021 Feb 1;27(3):689-703.
  • Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T. Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol. 2005 Feb;2(2):108-13.
  • Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev. 2008 Apr;222:316-27.
  • T, Itoh K. Current status and future perspective of cancer vaccine development. Gan To Kagaku Ryoho. 2011 Apr;38(4):503-8.
  • Arab A, Yazdian-Robati R, Behravan J. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Arch Immunol Ther Exp (Warsz). 2020 Jan 9;68(1):2.
  • Zhu SY, Yu KD. Breast Cancer Vaccines: Disappointing or Promising? Front Immunol. 2022 Jan 28;13:828386.
  • Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016 Jul;21(5):821-33.
  • Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 2021 Jan 20;6(1):26.
  • Kinoshita T, Terai H, Yaguchi T. Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life (Basel). 2021 Sep 30;11(10):1029.
  • Wrobel P, Ahmed S. Current status of immunotherapy in metastatic colorectal cancer. Int J Colorectal Dis. 2019 Jan;34(1):13-25.
  • Shahnazari M, Samadi P, Pourjafar M, Jalali A. Therapeutic vaccines for colorectal cancer: The progress and future prospect. Int Immunopharmacol. 2020 Nov;88:106944.
  • Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021 Sep 3;17(14):3837-49.
  • Silva D, Abreu-Mendes P, Mourato C, Martins D, Cruz R, Mendes F. Prostate cancer, new treatment advances - immunotherapy. Actas Urol Esp (Engl Ed). 2020 Sep;44(7):458-68.
  • Bilusic M, Madan RA, Gulley JL. Immunotherapy of Prostate Cancer: Facts and Hopes. Clin Cancer Res. 2017 Nov 15;23(22):6764-70.
  • Patel D, McKay R, Parsons JK. Immunotherapy for Localized Prostate Cancer: The Next Frontier? Urol Clin North Am. 2020 Nov;47(4):443-56.
  • Hammers H. Immunotherapy in kidney cancer: the past, present, and future. Curr Opin Urol. 2016 Nov;26(6):543-7
  • Bedke J, Stühler V, Stenzl A, Brehmer B. Immunotherapy for kidney cancer: status quo and the future. Curr Opin Urol. 2018 Jan;28(1):8-14.
  • Xu H, Zheng X, Zhang S, Yi X, Zhang T, Wei Q, Li H, Ai J. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma. Mol Cancer. 2021 Dec 6;20(1):159.
  • Curti BD, Faries MB. Recent Advances in the Treatment of Melanoma. N Engl J Med. 2021 Jun 10;384(23):2229-40.
  • Sondak VK, Sabel MS, Mulé JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2337s-2341s.
  • Vaccines Europe pipeline review 2022.Disponible en: https:// isanidad.com/wp-content/uploads/2022/12/Vaccines-Europepipeline-review-2022-1.pdf
  • American Association of Neurological Surgeons. Glioblastoma multiforme. Disponible en: https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme (consultado el 12 de diciembre de 2022).
  • World Cancer Research Fund International. Cancer trends. Disponible en: https://www.wcrf.org/cancer-trends/ (consultado el 12 de diciembre de 2022).
  • National Cancer Institute. Skin Cancer (Including melanoma) Patent Version. Disponible en: https://www.cancer.gov/types/skin (consultado el 12 de diciembre de 2022).
  • Skin Cancer Foundation. Skin cancer facts & statistics. Disponible: https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/ (consultado el 12 de diciembre de 2022).
  • World Cancer Research Fund International. Skin cancer statistics. Disponible en: https://www.wcrf.org/cancer-trends/skin-cancerstatistics/ (consultado el 12 de diciembre de 2022).
  • Thermo Fisher Scientific. Solid Tumor Research. Disponible en: https://www.thermofisher.com/be/en/home/life-science/cancerresearch/solid-tumor-research.html (consultado el 12 de diciembre de 2022).
Data source: Dialnet